Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist:A prespecified analysis from the SONAR trial

Autor: Dalane W. Kitzman, Di Xie, Hiddo J.L. Heerspink, Ricardo Correa-Rotter, Fan Fan Hou, Dick de Zeeuw, Hirofumi Makino, Vlado Perkovic, Donald E. Kohan, John J.V. McMurray, George L. Bakris, Hans-Henrik Parving, Peter Rossing

Publikováno v: Heerspink, H J L, Xie, D, Bakris, G, Correa-Rotter, R, Hou, F F, Kitzman, D W, Kohan, D, Makino, H, McMurray, J J V, Perkovic, V, Rossing, P, Parving, H H & de Zeeuw, D 2021, ' Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist : A prespecified analysis from the SONAR trial ', Journal of the American Society of Nephrology, vol. 32, no. 11 . https://doi.org/10.1681/ASN.2021030391
J Am Soc Nephrol
Journal of the American Society of Nephrology, 32(11), 2900-2911. AMER SOC NEPHROLOGY

BACKGROUND: Whether early reduction in albuminuria with atrasentan treatment predicts its long-term kidney-protective effect is unknown.METHODS: To assess the long-term effects on kidney outcomes of atrasentan versus placebo in the SONAR trial, we en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3229bb943a3e125089e6943a22428b7c
https://pure.au.dk/portal/da/publications/early-response-in-albuminuria-and-longterm-kidney-protection-during-treatment-with-an-endothelin-receptor-antagonist(d57ec1ed-ed75-4aa5-8909-6db92797b939).html